Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Detection of Recurrent Prostate Cancer Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients not Meeting the Phoenix Criteria for Biochemical Recurrence After Curative Radiotherapy.
Jansen BHE, van Leeuwen PJ, Wondergem M, van der Sluis TM, Nieuwenhuijzen JA, Knol RJJ, van Moorselaar RJA, van der Poel HG, Oprea-Lager DE, Vis AN. Jansen BHE, et al. Among authors: van der sluis tm, van leeuwen pj, van moorselaar rja, van der poel hg. Eur Urol Oncol. 2021 Oct;4(5):821-825. doi: 10.1016/j.euo.2020.01.002. Epub 2020 Feb 20. Eur Urol Oncol. 2021. PMID: 32088155
Screening and prostate-cancer mortality in a randomized European study.
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators. Schröder FH, et al. N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18. N Engl J Med. 2009. PMID: 19297566 Free article. Clinical Trial.
Should pathologists routinely report prostate tumour volume? The prognostic value of tumour volume in prostate cancer.
Wolters T, Roobol MJ, van Leeuwen PJ, van den Bergh RC, Hoedemaeker RF, van Leenders GJ, Schröder FH, van der Kwast TH. Wolters T, et al. Among authors: van den bergh rc, van leenders gj, van leeuwen pj, van der kwast th. Eur Urol. 2010 May;57(5):821-9. doi: 10.1016/j.eururo.2009.07.027. Epub 2009 Jul 29. Eur Urol. 2010. PMID: 19664875
Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100).
Roobol MJ, Schröder FH, van Leenders GL, Hessels D, van den Bergh RC, Wolters T, van Leeuwen PJ. Roobol MJ, et al. Among authors: van leenders gl, van den bergh rc, van leeuwen pj. Eur Urol. 2010 Dec;58(6):893-9. doi: 10.1016/j.eururo.2010.09.030. Epub 2010 Sep 26. Eur Urol. 2010. PMID: 20933321 Clinical Trial.
Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X, van Leeuwen PJ, Bul M, Otto SJ, de Koning HJ, Bangma CH, Schröder FH, Roobol MJ. Zhu X, et al. Among authors: van leeuwen pj. Eur Urol. 2011 Aug;60(2):330-6. doi: 10.1016/j.eururo.2011.05.013. Epub 2011 May 17. Eur Urol. 2011. PMID: 21601352 Clinical Trial.
Towards an optimal interval for prostate cancer screening.
van Leeuwen PJ, Roobol MJ, Kranse R, Zappa M, Carlsson S, Bul M, Zhu X, Bangma CH, Schröder FH, Hugosson J. van Leeuwen PJ, et al. Eur Urol. 2012 Jan;61(1):171-6. doi: 10.1016/j.eururo.2011.08.002. Epub 2011 Aug 10. Eur Urol. 2012. PMID: 21840117 Clinical Trial.
196 results